Abstract: The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RxSi(OH)4-x, (I) wherein: R is a (C1-C4)alkyl, and x=1 or 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.

Abstract: The invention concerns a methionine-derived peptidomimetic represented by the following general formula (II): R?X—C(O)—NH— with X=alkyl or alkyloxy (C1-C4); R??H The invention also concerns a composition for preventing or fighting cutaneous disorders associated to a mitochondrial dysfunction, and the use of a methionine-derived peptidomimetic as a cosmetic agent for protecting and/or stimulating the mitochondria of cutaneous cells.

Abstract: The invention concerns a cosmetic care method for opposing destructive effects of oxidative stress and its toxic by-products, comprising administering topically to a patient in need thereof, a derivative of formula (I): in which X is oxygen or sulphur. The invention especially applies to the domain of skin protection and more especially against cutaneous consequences of oxidative stress.

Abstract: The invention concerns a cosmetic care method for opposing destructive effects of oxidative stress and its toxic by-products, comprising administering topically to a patient in need thereof, a derivative of formula (I): in which X is oxygen or sulphur. The invention especially applies to the domain of skin protection and more especially against cutaneous consequences of oxidative stress.

Abstract: The invention concerns a methionine-derived peptidomimetic represented by the following general formula (II): R=X—C(O)—NH— with X=alkyl or alkyloxy (C1-C4); R?=H The invention also concerns a composition for preventing or fighting cutaneous disorders associated to a mitochondrial dysfunction, and the use of a methionine-derived peptidomimetic as a cosmetic agent for protecting and/or stimulating the mitochondria of cutaneous cells.

Abstract: The invention has for object the cosmetic use and as neurotrophic agent of at least an indolic auxin conjugate with general formula (I): in which: n is equal to 1, 2 et 3, and m is equal to 1 et 2.

Abstract: A cosmetic composition intended for protecting skin against stress generating free radicals or reactive oxygen species is disclosed. The cosmetic composition comprises a physiologically compatible excipient and a thiazolidine compound. Methods of protecting skin generally and against cutaneous consequences of oxidative stress are also disclosed.

Abstract: The present invention relates to an algal adduct of the citrullinylarginine natural dipeptide as well as to its dermatological use and the use of chemical analogs issued from the same dipeptide displaying no toxic potential, as skin and phanera care and treatment agents, the said analogs having the following general formula (I): in which: R1 represents an acyl or acycloxy radical, R2 represents a hydroxyl, amine, alkylamine or alcoxy radical, R3 represents a hydrogen atom or a hydroxyl radical.

Abstract: The purpose of the invention concerns a family of pseudodipeptides which are coupling products between tryptamine, an indole-primary amine, and a selection of alpha-amino acids, the said pseudodipeptides having the following general formula (I): in which: R1 represents a hydrogen atom, an acyl or acyloxy radical, R2 represents the side chain of an alpha-amino acid chosen among L-glutamic acid, L-arginine, L-cysteine, L-methionine, L-histidine, L-tryptophan, L-tyrosine. The present invention also concerns the process for the preparation of said products as well as their applications in neurocosmetic compositions or as active substances on the cutaneous nervous system.

Abstract: The present invention relates to an algal adduct of the citrullinylarginine natural dipeptide as well as to its dermatological use and the use of chemical analogs issued from the same dipeptide displaying no toxic potential, as skin and phanera care and treatment agents, the said analogs having the following general formula (I): in which: R1 represents an acyl or acycloxy radical, R2 represents a hydroxyl, amine, alkylamine or alcoxy radical, R3 represents a hydrogen atom or a hydroxyl radical.

Abstract: A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I) where R1 is a group bound by a peptidic bond and selected from the group consisting of a hydrogen atom, a hydroxyl group, an acyl group, acyloxy group and a substituted or unsubstituted aminoacid; R2 is a group bond by a peptidic bond and selected from the group consisting of a hydroxyl group, an amine group, an alkoxy group, an alkylamine group, a silyloxy group or a substituted or unsubstituted aminoacid; and n is 3 or 4.

Abstract: The invention concerns a complex containing biologically assimilable orthosilicic acid and a process of preparation of said complex. In this complex, orthosilicic acid is complexed with a polypeptide and the complex is under solid, stable and concentrated form. The present invention also concerns cosmetic or therapeutic compositions, and a nutritional supplement containing said complex.

Abstract: Cosmetic composition useful notably in the whitening of skin which it includes, in association with any suitable excipient, at least one compound of the following general formula (I): wherein: R1 represents a hydrogen atom, a linear or branched alkyl group or a thiazoline group, R2 represents a hydrogen atom, a linear or branched alkyl group or a linear or branched alkyl group substituted by a carboxyl, a hydroxyl, an amine or a thiol group, R3 represents a hydrogen atom, a linear or branched alkyl group, an arylalkyl group, an acyl group or an acyloxy group, R4 represents a hydrogen atom or a linear or branched alkyl group, R5 represents a hydrogen atom, a hydroxyl group or a linear or branched alkyl group.

Abstract: Silicon compound of general formula a), in which A, B, C, D are radicals which are different from OH and are covalently bonded to Si; two or three of these bond that are linked to Si are Si—O—C, Si—S—C or Si—N—C type bonds and are hydrolyzable in vivo, forming Si—OH bonds that are biologically active especially when in contact with living tissue, the A and D bonds of formula b) being invariably hydrolyzable; at least one of the hydrolyzable bonds corresponds to an acyloxy, aryloxy or vinyloxy radical; at least one of the compounds obtained after hydrolysis of the hydrolyzable bonds is a stabilizer, and the non-hydrolyzable bonds, which are of the Si—C type, correspond to hydrocarbon or fluorocarbon radicals for which Si is not directly linked to the phenyl ring.

Abstract: Organo silicon compound having the following general formula (I): R4—Si (OR1) (OR2) (R3)  (I) where R1 and R2 each one independently represent an atom of hydrogen or an alkyl group, R3 represents an hydrogen atom, an hydroxyl group, an amine group, an alkyl group, an alkoxy or a carboxylate group, and at least one of the OR1, OR2 or R3 groups represents an hydroxyl group, R4 represents an alkyl group substituted or not by a functional group such as, notably, an alkyl phosphate group or an alkyl phosphonate group, or any other group for which the R4—Si bond is not hydrolyzable, and the compound: is in solid form, and/or is possibly associated with at least one stabilizer, and/or is possibly associated with at least one dispersant.

Abstract: A process for the preparation of biologically active silicon compounds by hydrolysis of a precursor which produces a compound which prevents the formation of polymers from the silicon hydrolyzed bonds.

Abstract: Process of assessment of ocular dysfunctions, characterized in that the patient's eye (1) is placed to a previously defined distance from a lightening glare source (3), so that he can visualize a target (4) placed next to the lightening glare source (3), then the target (4) is approached from the source (3) so that the patient becomes unable to distinguish the target (4) from the source (3) and then, the target (4) is slowly taken away from the source (3), up to the exact moment when the patient distinguishes again the target (4), and at this time, the incident light angle o between the source (3) and the target (4) is measured.

Abstract: Products for cutaneous application with cosmetic and/or therapeutic effects, containing one or more active substances. This or these substances are carried by the microspheres of a polymer, dispersed in a liquid in which this polymer is not soluble.

Abstract: Product of condensation of a silanol or a silanol derivative, which comprises an Si atom carrying two organic radicals and two oxygen atoms connected to organic groups other than the radicals; at least one of these organic groups carries at least one NH and a NH.sub.2.

Abstract: Production of non-saponifiable compounds from natural substances such as plants, mushroom mycelium or bacteria, by extraction by means of an organic solvent. The solvent is an aliphatic or aryl ester, the molecule of which comprises at least 10 carbon atoms and preferably more than 12 carbon atoms.